Anke Van Herck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anke Van Herck has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Stijn E. Verleden
Department of Thoracic and Vascular Surgery & Pneumology, Antwerp University Hospital, Edegem, Belgium; Antwerp Surgical Training Anatomy and Research Centre (ASTARC), University of Antwerp, Antwerpen, Belgium
33 shared publications - Bart M. Vanaudenaerde
Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
32 shared publications - Tobias Heigl
KU Leuven, Leuven, Belgium
25 shared publications - Dirk Van Raemdonck
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
19 shared publications R. Vos
15 shared publicationsAnnelore Sacreas
Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium
13 shared publications
Latest Publications
- 29 May 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (4) , 2001720
SuccessfulPseudomonas aeruginosaeradication improves outcomes after lung transplantation: a retrospective cohort analysis
Long-term survival after lung transplantation (LTx) is hampered by development of chronic lung allograft dysfunction (CLAD).Pseudomonas aeruginosais an established risk factor for CLAD. Therefore, we investigated the effect ofP. aeruginosaeradication on CLAD-free and graft survival.Patients who underwent first LTx between July, 1991, and February, 2016, and were free from CLAD, were retrospectively classified according toP. aeruginosapresence in respiratory samples between September, 2011, and September, 2016.P. aeruginosa-positive patients were subsequently stratified according to success ofP. aeruginosaeradication following targeted antibiotic treatment. CLAD-free and graft survival were compared betweenP. aeruginosa-positive andP. aeruginosa-negative patients; and between patients with or without successfulP. aeruginosaeradication. In addition, pulmonary function was assessed during the first year followingP. aeruginosaisolation in both groups.CLAD-free survival ofP. aeruginosa-negative patients (n=443) was longer compared withP. aeruginosa-positive patients (n=95) (p=0.045). Graft survival ofP. aeruginosa-negative patients (n=443, 82%) was better compared withP. aeruginosa-positive patients (n=95, 18%) (pP. aeruginosa-eradicated patients demonstrated longer CLAD-free and graft survival compared with patients with persistentP. aeruginosa. Pulmonary function was higher in successfullyP. aeruginosa-eradicated patients compared with unsuccessfully eradicated patients (p=0.035).P. aeruginosaeradication after LTx improves CLAD-free and graft survival and maintains pulmonary function. Therefore, earlyP. aeruginosadetection and eradication should be pursued.
- 29 May 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (4) , 2001720
SuccessfulPseudomonas aeruginosaeradication improves outcomes after lung transplantation: a retrospective cohort analysis
Long-term survival after lung transplantation (LTx) is hampered by development of chronic lung allograft dysfunction (CLAD).Pseudomonas aeruginosais an established risk factor for CLAD. Therefore, we investigated the effect ofP. aeruginosaeradication on CLAD-free and graft survival.Patients who underwent first LTx between July, 1991, and February, 2016, and were free from CLAD, were retrospectively classified according toP. aeruginosapresence in respiratory samples between September, 2011, and September, 2016.P. aeruginosa-positive patients were subsequently stratified according to success ofP. aeruginosaeradication following targeted antibiotic treatment. CLAD-free and graft survival were compared betweenP. aeruginosa-positive andP. aeruginosa-negative patients; and between patients with or without successfulP. aeruginosaeradication. In addition, pulmonary function was assessed during the first year followingP. aeruginosaisolation in both groups.CLAD-free survival ofP. aeruginosa-negative patients (n=443) was longer compared withP. aeruginosa-positive patients (n=95) (p=0.045). Graft survival ofP. aeruginosa-negative patients (n=443, 82%) was better compared withP. aeruginosa-positive patients (n=95, 18%) (pP. aeruginosa-eradicated patients demonstrated longer CLAD-free and graft survival compared with patients with persistentP. aeruginosa. Pulmonary function was higher in successfullyP. aeruginosa-eradicated patients compared with unsuccessfully eradicated patients (p=0.035).P. aeruginosaeradication after LTx improves CLAD-free and graft survival and maintains pulmonary function. Therefore, earlyP. aeruginosadetection and eradication should be pursued.
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S305
Blood Eosinophilia Predicts Poor Outcome in Lung Transplant Recipients
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S305
Blood Eosinophilia Predicts Poor Outcome in Lung Transplant Recipients
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S305
Circulating Follicular Helper T Cells are Decreased in Chronic Lung Allograft Dysfunction
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S305
Circulating Follicular Helper T Cells are Decreased in Chronic Lung Allograft Dysfunction
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S303
Successful Pseudomonas aeruginosa Eradication Improves Outcomes after Lung Transplantation
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S303
Successful Pseudomonas aeruginosa Eradication Improves Outcomes after Lung Transplantation
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S472
Dynamic Evolution of Chronic Lung Allograft Rejection in the Mouse
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S472
Dynamic Evolution of Chronic Lung Allograft Rejection in the Mouse
- Open Access
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S356
Flow Controlled Ventilation during EVLP Improves Oxygenation and Preserves Alveolar Recruitment
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S356
Open AccessFlow Controlled Ventilation during EVLP Improves Oxygenation and Preserves Alveolar Recruitment
- 19 March 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 181 (1) , 115-125
Behavior of metastatic breast cancer according to subtype
Purpose To explore the impact of breast cancer subtype on metastatic behavior and long-term outcome defined as breast cancer specific survival (BCSS). Methods Retrospective single centre cross-sectional study of 5972 patients with newly diagnosed, unilateral first diagnosis of breast cancer, diagnosed 2000–2010. Patients had either early breast cancer (EBC) treated primarily by surgery (SURG n = 5072), neoadjuvant systemic therapy (NEO n = 592), or upfront metastatic disease (META n = 308). Surrogate breast cancer subtypes were defined according to classical pathological criteria. Analysis was performed using Kaplan–Meier method and logistic/Cox regression. Results After median follow-up time of 103.6 months (IQR 73.4–139.2 months), 817 patients with EBC at diagnosis (14.4%) developed distant metastases of which 621 (12.2%) SURG and 196 (33.1%) NEO. Metastasis rate after EBC was: LuminalA 8.1%, LuminalB1(HER2−) 20.4%, LuminalB2(HER2+) without (neo)adjuvant trastuzumab 21.7%, LuminalB2(HER2+) with trastuzumab 9.0%, HER2Positive(ER−) without trastuzumab 30.0%, HER2Positive(ER−) with trastuzumab 19.9% and TripleNegative 25.3%. There were major differences in site of first metastases according to subtype. For single site first metastases, median BCSS assessed from time of metastases was worst for brain localization (13.9 months) and best for bone (48.4 months). Multiple sites of first metastases had worse BCSS from date of metastases than single site first metastases (median BCSS for 1 site 40.0, 2 sites 27.1, ≥ 3 sites 20.5 months). Median BCSS from date of metastases is longer in upfront metastases compared to secondary metastases after EBC (43.4 vs. 27.9 months). Conclusions Tumor subtype influences the metastatic behavior and survival after development of distant metastases.
- 19 March 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 181 (1) , 115-125
Behavior of metastatic breast cancer according to subtype
Purpose To explore the impact of breast cancer subtype on metastatic behavior and long-term outcome defined as breast cancer specific survival (BCSS). Methods Retrospective single centre cross-sectional study of 5972 patients with newly diagnosed, unilateral first diagnosis of breast cancer, diagnosed 2000–2010. Patients had either early breast cancer (EBC) treated primarily by surgery (SURG n = 5072), neoadjuvant systemic therapy (NEO n = 592), or upfront metastatic disease (META n = 308). Surrogate breast cancer subtypes were defined according to classical pathological criteria. Analysis was performed using Kaplan–Meier method and logistic/Cox regression. Results After median follow-up time of 103.6 months (IQR 73.4–139.2 months), 817 patients with EBC at diagnosis (14.4%) developed distant metastases of which 621 (12.2%) SURG and 196 (33.1%) NEO. Metastasis rate after EBC was: LuminalA 8.1%, LuminalB1(HER2−) 20.4%, LuminalB2(HER2+) without (neo)adjuvant trastuzumab 21.7%, LuminalB2(HER2+) with trastuzumab 9.0%, HER2Positive(ER−) without trastuzumab 30.0%, HER2Positive(ER−) with trastuzumab 19.9% and TripleNegative 25.3%. There were major differences in site of first metastases according to subtype. For single site first metastases, median BCSS assessed from time of metastases was worst for brain localization (13.9 months) and best for bone (48.4 months). Multiple sites of first metastases had worse BCSS from date of metastases than single site first metastases (median BCSS for 1 site 40.0, 2 sites 27.1, ≥ 3 sites 20.5 months). Median BCSS from date of metastases is longer in upfront metastases compared to secondary metastases after EBC (43.4 vs. 27.9 months). Conclusions Tumor subtype influences the metastatic behavior and survival after development of distant metastases.
- 1 February 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (2) , 176-183
Influence of azithromycin and allograft rejection on the post–lung transplant microbiota
- 1 February 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (2) , 176-183
Influence of azithromycin and allograft rejection on the post–lung transplant microbiota
- 20 January 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (2) , e13781
Identification and characterization of chronic lung allograft dysfunction patients with mixed phenotype: A single‐center study
Rationale: Patients can change chronic lung allograft dysfunction (CLAD) phenotype, especially from BOS to mixed phenotype. Our aim was to further characterize these patients.Method: Mixed CLAD was defined as a restrictive physiology with persistent CT opacities, after initial bronchiolitis obliterans syndrome (BOS) diagnosis. The incidence, prognosis, pulmonary function, radiology, pathology, and airway inflammation were compared between patients with restrictive allograft syndrome (RAS) and mixed CLAD.Result: A total of 268 (44%) patients developed CLAD of which 47 (18%) were diagnosed with RAS “ab initio,” 215 (80%) with BOS, and 6 (2%) an undefined phenotype. Twenty‐five patients developed a mixed CLAD phenotype (24 BOS to mixed and 1 RAS to mixed). Survival after mixed phenotype diagnosis was comparable (P = .39) to RAS. More emphysema patients developed a mixed phenotype (P = .020) compared to RAS ab initio, while mixed CLAD patients had a lower FEV1 (P < .0001) and FEV1/FVC (P = .0002) at diagnosis compared to RAS ab initio. CT scans in patients with the mixed phenotype demonstrated apical predominance of the opacities (P = .0034) with pleuroparenchymal fibroelastosis on histopathology.Conclusion: We further characterized patients with a mixed phenotype of CLAD. Although the survival after diagnosis was comparable to RAS ab initio patients, there was a difference in demography, pulmonary function, radiology, and pathology.
- 20 January 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (2) , e13781
Identification and characterization of chronic lung allograft dysfunction patients with mixed phenotype: A single‐center study
Rationale: Patients can change chronic lung allograft dysfunction (CLAD) phenotype, especially from BOS to mixed phenotype. Our aim was to further characterize these patients.Method: Mixed CLAD was defined as a restrictive physiology with persistent CT opacities, after initial bronchiolitis obliterans syndrome (BOS) diagnosis. The incidence, prognosis, pulmonary function, radiology, pathology, and airway inflammation were compared between patients with restrictive allograft syndrome (RAS) and mixed CLAD.Result: A total of 268 (44%) patients developed CLAD of which 47 (18%) were diagnosed with RAS “ab initio,” 215 (80%) with BOS, and 6 (2%) an undefined phenotype. Twenty‐five patients developed a mixed CLAD phenotype (24 BOS to mixed and 1 RAS to mixed). Survival after mixed phenotype diagnosis was comparable (P = .39) to RAS. More emphysema patients developed a mixed phenotype (P = .020) compared to RAS ab initio, while mixed CLAD patients had a lower FEV1 (P < .0001) and FEV1/FVC (P = .0002) at diagnosis compared to RAS ab initio. CT scans in patients with the mixed phenotype demonstrated apical predominance of the opacities (P = .0034) with pleuroparenchymal fibroelastosis on histopathology.Conclusion: We further characterized patients with a mixed phenotype of CLAD. Although the survival after diagnosis was comparable to RAS ab initio patients, there was a difference in demography, pulmonary function, radiology, and pathology.
- 23 October 2019
- Published by Frontiers Media SA in Transplant International
- Vol. 33 (2) , 216-228
Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation: a single‐center experience and review of literature
Limited results about treatment with total lymphoid irradiation (TLI) in lung transplant (LTx) recipients suffering from progressive bronchiolitis obliterans syndrome (BOS) have been reported. We performed a retrospective analysis of all LTx recipients undergoing TLI for progressive BOS in our center, focusing on long‐term outcomes regarding overall survival and lung allograft function. Treatment with TLI (2004‐2017, n=20, 1 BOS stage 1, 6 BOS stage 2 and 13 BOS stage 3) resulted in significant attenuation of the FEV1‐decline in the majority of patients, mainly in those with a rapid decline (p=0.0005). This allowed bridging to redo‐transplantation in 5 patients. However, 3 patients progressed from BOS to RAS following prior TLI. Overall patient survival was 44% at 2 years post‐TLI and 38% after 17 years. Generally, TLI was well tolerated, with limited side effects and no serious adverse events. TLI may attenuate the decline in FEV1 of LTx recipients with rapid progressive BOS and could thus help to bridge selected patients to redo‐transplantation.
- 23 October 2019
- Published by Frontiers Media SA in Transplant International
- Vol. 33 (2) , 216-228
Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation: a single‐center experience and review of literature
Limited results about treatment with total lymphoid irradiation (TLI) in lung transplant (LTx) recipients suffering from progressive bronchiolitis obliterans syndrome (BOS) have been reported. We performed a retrospective analysis of all LTx recipients undergoing TLI for progressive BOS in our center, focusing on long‐term outcomes regarding overall survival and lung allograft function. Treatment with TLI (2004‐2017, n=20, 1 BOS stage 1, 6 BOS stage 2 and 13 BOS stage 3) resulted in significant attenuation of the FEV1‐decline in the majority of patients, mainly in those with a rapid decline (p=0.0005). This allowed bridging to redo‐transplantation in 5 patients. However, 3 patients progressed from BOS to RAS following prior TLI. Overall patient survival was 44% at 2 years post‐TLI and 38% after 17 years. Generally, TLI was well tolerated, with limited side effects and no serious adverse events. TLI may attenuate the decline in FEV1 of LTx recipients with rapid progressive BOS and could thus help to bridge selected patients to redo‐transplantation.